Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review

Journal of the American College of Cardiology

Volumn 72, Issue 21, 2018, Pages 2625-2641

  Taqueti, Viviany R ^a   Di Carli, Marcelo F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

coronary flow reserve; coronary microvascular dysfunction; heart failure with preserved ejection fraction; ischemic heart disease; nonobstructive coronary artery disease

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC ACID DERIVATIVE; SHORT ACTING DRUG;

ADVERSE OUTCOME; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY MICROVASCULAR DISEASE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE SEVERITY; FUNCTION TEST; FUNCTIONAL DISEASE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; INSULIN RESISTANCE; INVASIVE PROCEDURE; MICROANGIOPATHY; MICROCIRCULATION; NON INVASIVE MEASUREMENT; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVIEW; RISK REDUCTION; DIAGNOSTIC IMAGING; FRACTIONAL FLOW RESERVE; LITERATURE; PHYSIOLOGY;

CORONARY ARTERY DISEASE; CORONARY CIRCULATION; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HUMANS; MICROCIRCULATION; REVIEW LITERATURE AS TOPIC;

EID: 85056336418     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.09.042     Document Type: Review

References (117)

1. Benjamin, E.J., Virani, S.S., Callaway, C.W., et al., for the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. [Published correction appears in Circulation 2018;137:e493] Circulation 137 (2018), e67–e492.
2. Jespersen, L., Hvelplund, A., Abildstrøm, S.Z., et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J 33 (2012), 734–744.
3. Maddox, T.M., Stanislawski, M.A., Grunwald, G.K., et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA 312 (2014), 1754–1763.
4. Patel, M.R., Peterson, E.D., Dai, D., et al. Low diagnostic yield of elective coronary angiography. [Published correction appears in N Engl J Med 2010;363:498] N Engl J Med 362 (2010), 886–895.
5. Rozanski, A., Gransar, H., Hayes, S.W., et al. Temporal trends in the frequency of inducible myocardial ischemia during cardiac stress testing: 1991 to 2009. J Am Coll Cardiol 61 (2013), 1054–1065.
6. Yeh, R.W., Sidney, S., Chandra, M., Sorel, M., Selby, J.V., Go, A.S., Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362 (2010), 2155–2165.
7. Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
8. Bairey Merz, C.N., Pepine, C.J., Walsh, M.N., Fleg, J.L., Ischemia and No Obstructive Coronary Artery Disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation 135 (2017), 1075–1092.
9. Camici, P.G., Crea, F., Coronary microvascular dysfunction. N Engl J Med 356 (2007), 830–840.
10. Chilian, W.M., Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation 95 (1997), 522–528.
11. Pepine, C.J., Anderson, R.D., Sharaf, B.L., et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia: results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 55 (2010), 2825–2832.
12. Ong, P., Camici, P.G., Beltrame, J.F., et al., for the Coronary Vasomotion Disorders International Study Group (COVADIS). International standardization of diagnostic criteria for microvascular angina. Int J Cardiol 250 (2018), 16–20.
13. Shimokawa, H., 2014 Williams Harvey Lecture: importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart J 35 (2014), 3180–3193.
14. Khuddus, M.A., Pepine, C.J., Handberg, E.M., et al. An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). J Interv Cardiol 23 (2010), 511–519.
15. Murthy, V.L., Naya, M., Taqueti, V.R., et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation 129 (2014), 2518–2527.
16. Taqueti, V.R., Hachamovitch, R., Murthy, V.L., et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation 131 (2015), 19–27.
17. Farias, M. III, Gorman, M.W., Savage, M.V., Feigl, E.O., Plasma ATP during exercise: possible role in regulation of coronary blood flow. Am J Physiol Heart Circ Physiol 288 (2005), H1586–H1590.
18. Amann, K., Wiest, G., Zimmer, G., Gretz, N., Ritz, E., Mall, G., Reduced capillary density in the myocardium of uremic rats–a stereological study. Kidney Int 42 (1992), 1079–1085.
19. Asghar, O., Al-Sunni, A., Khavandi, K., et al. Diabetic cardiomyopathy. Clin Sci (Lond) 116 (2009), 741–760.
20. Mosseri, M., Schaper, J., Admon, D., et al. Coronary capillaries in patients with congestive cardiomyopathy or angina pectoris with patent main coronary arteries. Ultrastructural morphometry of endomyocardial biopsy samples. Circulation 84 (1991), 203–210.
21. Mosseri, M., Yarom, R., Gotsman, M.S., Hasin, Y., Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 74 (1986), 964–972.
22. Suzuki, H., Takeyama, Y., Koba, S., Suwa, Y., Katagiri, T., Small vessel pathology and coronary hemodynamics in patients with microvascular angina. Int J Cardiol 43 (1994), 139–150.
23. Opherk, D., Zebe, H., Weihe, E., et al. Reduced coronary dilatory capacity and ultrastructural changes of the myocardium in patients with angina pectoris but normal coronary arteriograms. Circulation 63 (1981), 817–825.
24. Richardson, P.J., Livesley, B., Oram, S., Olsen, E.G., Armstrong, P., Angina pectoris with normal coronary arteries. Transvenous myocardial biopsy in diagnosis. Lancet 2 (1974), 677–680.
25. Egashira, K., Inou, T., Hirooka, Y., et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 91 (1993), 29–37.
26. Di Carli, M.F., Charytan, D., McMahon, G.T., Ganz, P., Dorbala, S., Schelbert, H.R., Coronary circulatory function in patients with the metabolic syndrome. J Nucl Med 52 (2011), 1369–1377.
27. Di Carli, M.F., Janisse, J., Grunberger, G., Ager, J., Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 41 (2003), 1387–1393.
28. Yokoyama, I., Momomura, S., Ohtake, T., et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 30 (1997), 1472–1477.
29. Dayanikli, F., Grambow, D., Muzik, O., Mosca, L., Rubenfire, M., Schwaiger, M., Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 90 (1994), 808–817.
30. Pitkänen, O.P., Raitakari, O.T., Niinikoski, H., et al. Coronary flow reserve is impaired in young men with familial hypercholesterolemia. J Am Coll Cardiol 28 (1996), 1705–1711.
31. Hamasaki, S., Al Suwaidi, J., Higano, S.T., Miyauchi, K., Holmes, D.R. Jr., Lerman, A., Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol 35 (2000), 1654–1660.
32. Laine, H., Raitakari, O.T., Niinikoski, H., et al. Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol 32 (1998), 147–153.
33. Quercioli, A., Pataky, Z., Montecucco, F., et al. Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. J Am Coll Cardiol Img 5 (2012), 805–815.
34. Campisi, R., Czernin, J., Schöder, H., et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation 98 (1998), 119–125.
35. Charytan, D.M., Skali, H., Shah, N.R., et al. Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage. Kidney Int 93 (2018), 501–509.
36. Shah, N.R., Charytan, D.M., Murthy, V.L., et al. Prognostic value of coronary flow reserve in patients with dialysis-dependent ESRD. J Am Soc Nephrol 27 (2016), 1823–1829.
37. Majmudar, M.D., Murthy, V.L., Shah, R.V., et al. Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. Eur Heart J Cardiovasc Imaging 16 (2015), 900–909.
38. Neglia, D., Michelassi, C., Trivieri, M.G., et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 105 (2002), 186–193.
39. Ong, P., Athanasiadis, A., Borgulya, G., Mahrholdt, H., Kaski, J.C., Sechtem, U., High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol 59 (2012), 655–662.
40. Lee, B.K., Lim, H.S., Fearon, W.F., et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation 131 (2015), 1054–1060.
41. De Bruyne, B., Hersbach, F., Pijls, N.H., et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but “Normal” coronary angiography. Circulation 104 (2001), 2401–2406.
42. Gould, K.L., Nakagawa, Y., Nakagawa, K., et al. Frequency and clinical implications of fluid dynamically significant diffuse coronary artery disease manifest as graded, longitudinal, base-to-apex myocardial perfusion abnormalities by noninvasive positron emission tomography. Circulation 101 (2000), 1931–1939.
43. Hoffmann, U., Ferencik, M., Udelson, J.E., et al., for the PROMISE Investigators. Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation 135 (2017), 2320–2332.
44. SCOT-HEART investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. [Published correction appears in Lancet 2015;385:2354] Lancet 385 (2015), 2383–2391.
45. Bairey Merz, C.N., Handberg, E.M., Shufelt, C.L., et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J 37 (2016), 1504–1513.
46. Mygind, N.D., Michelsen, M.M., Pena, A., et al. Coronary microvascular function and cardiovascular risk factors in women with angina pectoris and no obstructive coronary artery disease: the iPOWER Study. J Am Heart Assoc, 5, 2016, e003064.
47. Sara, J.D., Widmer, R.J., Matsuzawa, Y., Lennon, R.J., Lerman, L.O., Lerman, A., Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. J Am Coll Cardiol Intv 8 (2015), 1445–1453.
48. Shah, N.R., Cheezum, M.K., Veeranna, V., et al. Ranolazine in symptomatic diabetic patients without obstructive coronary artery disease: impact on microvascular and diastolic function. J Am Heart Assoc, 6, 2017, e005027.
49. Taqueti, V.R., Solomon, S.D., Shah, A.M., et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 39 (2018), 840–849.
50. Task Force Members, Montalescot, G., Sechtem, U., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34 (2013), 2949–3003.
51. Feher, A., Sinusas, A.J., Quantitative assessment of coronary microvascular function: dynamic single-photon emission computed tomography, positron emission tomography, ultrasound, computed tomography, and magnetic resonance imaging. Circ Cardiovasc Imaging, 10, 2017, e006427.
52. Taqueti, V.R., Everett, B.M., Murthy, V.L., et al. Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. Circulation 131 (2015), 528–535.
53. Gupta, A., Taqueti, V.R., van de Hoef, T.P., et al. Integrated noninvasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. Circulation 136 (2017), 2325–2336.
54. 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 54 (2009), 150–156.
55. Ziadi, M.C., Dekemp, R.A., Williams, K.A., et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol 58 (2011), 740–748.
56. Liu, A., Wijesurendra, R.S., Liu, J.M., et al. Diagnosis of microvascular angina using cardiac magnetic resonance. J Am Coll Cardiol 71 (2018), 969–979.
57. Doyle, M., Weinberg, N., Pohost, G.M., et al. Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol Img 3 (2010), 1030–1036.
58. Cortigiani, L., Rigo, F., Gherardi, S., et al. Additional prognostic value of coronary flow reserve in diabetic and nondiabetic patients with negative dipyridamole stress echocardiography by wall motion criteria. J Am Coll Cardiol 50 (2007), 1354–1361.
59. Gan, L.M., Svedlund, S., Wittfeldt, A., et al. Incremental value of transthoracic Doppler echocardiography-assessed coronary flow reserve in patients with suspected myocardial ischemia undergoing myocardial perfusion scintigraphy. J Am Heart Assoc, 6, 2017, e004875.
60. Rigo, F., Sicari, R., Gherardi, S., Djordjevic-Dikic, A., Cortigiani, L., Picano, E., Prognostic value of coronary flow reserve in medically treated patients with left anterior descending coronary disease with stenosis 51% to 75% in diameter. Am J Cardiol 100 (2007), 1527–1531.
61. Lee, J.M., Jung, J.H., Hwang, D., et al. Coronary flow reserve and microcirculatory resistance in patients with intermediate coronary stenosis. J Am Coll Cardiol 67 (2016), 1158–1169.
62. Tonino, P.A., De Bruyne, B., Pijls, N.H., et al., FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360 (2009), 213–224.
63. De Bruyne, B., Pijls, N.H., Kalesan, B., et al., FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367 (2012), 991–1001.
64. Echavarria-Pinto, M., Escaned, J., Macías, E., et al. Disturbed coronary hemodynamics in vessels with intermediate stenoses evaluated with fractional flow reserve: a combined analysis of epicardial and microcirculatory involvement in ischemic heart disease. Circulation 128 (2013), 2557–2566.
65. Davies, J.E., Sen, S., Escaned, J., Instantaneous wave-free ratio versus fractional flow reserve. N Engl J Med 377 (2017), 1597–1598.
66. Götberg, M., Christiansen, E.H., Gudmundsdottir, I.J., et al., for the iFR-SWEDEHEART Investigators. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med 376 (2017), 1813–1823.
67. Sen, S., Petraco, R., Mayet, J., Davies, J., Wave intensity analysis in the human coronary circulation in health and disease. Curr Cardiol Rev 10 (2014), 17–23.
68. Broyd, C.J., Hernández-Pérez, F., Segovia, J., et al. Identification of capillary rarefaction using intracoronary wave intensity analysis with resultant prognostic implications for cardiac allograft patients. Eur Heart J 39 (2018), 1807–1814.
69. Brush, J.E. Jr., Cannon, R.O. III, Schenke, W.H., et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 319 (1988), 1302–1307.
70. Rajappan, K., Rimoldi, O.E., Camici, P.G., Bellenger, N.G., Pennell, D.J., Sheridan, D.J., Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation 107 (2003), 3170–3175.
71. Bravo, P.E., Zimmerman, S.L., Luo, H.C., et al. Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 6 (2013), 210–217.
72. Cecchi, F., Olivotto, I., Gistri, R., Lorenzoni, R., Chiriatti, G., Camici, P.G., Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349 (2003), 1027–1035.
73. Dorbala, S., Vangala, D., Bruyere, J. Jr., et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. J Am Coll Cardiol HF 2 (2014), 358–367.
74. Pelliccia, F., Kaski, J.C., Crea, F., Camici, P.G., Pathophysiology of Takotsubo syndrome. Circulation 135 (2017), 2426–2441.
75. Templin, C., Ghadri, J.R., Diekmann, J., et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med 373 (2015), 929–938.
76. Dweck, M.R., Boon, N.A., Newby, D.E., Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol 60 (2012), 1854–1863.
77. Dilsizian, V., Bonow, R.O., Epstein, S.E., Fananapazir, L., Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 22 (1993), 796–804.
78. Pasupathy, S., Tavella, R., Beltrame, J.F., Myocardial infarction with nonobstructive coronary arteries (MINOCA): the past, present, and future management. Circulation 135 (2017), 1490–1493.
79. Schindler, T.H., Cardenas, J., Prior, J.O., et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 47 (2006), 1188–1195.
80. Tona, F., Serra, R., Di Ascenzo, L., et al. Systemic inflammation is related to coronary microvascular dysfunction in obese patients without obstructive coronary disease. Nutr Metab Cardiovasc Dis 24 (2014), 447–453.
81. Bajaj, N.S., Osborne, M.T., Gupta, A., et al. Coronary microvascular dysfunction and cardiovascular risk in obese patients. J Am Coll Cardiol 72 (2018), 707–717.
82. Peters, S.A., Huxley, R.R., Woodward, M., Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57 (2014), 1542–1551.
83. Murthy, V.L., Naya, M., Foster, C.R., et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 126 (2012), 1858–1868.
84. Osborne, M.T., Bajaj, N.S., Taqueti, V.R., et al. Coronary microvascular dysfunction identifies patients at high risk of adverse events across cardiometabolic diseases. J Am Coll Cardiol 70 (2017), 2835–2837.
85. Chade, A.R., Brosh, D., Higano, S.T., Lennon, R.J., Lerman, L.O., Lerman, A., Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease. Kidney Int 69 (2006), 266–271.
86. Everett, B.M., Cook, N.R., Magnone, M.C., et al. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. Circulation 123 (2011), 2811–2818.
87. Dryer, K., Gajjar, M., Narang, N., et al. Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol 314 (2018), H1033–H1042.
88. Kato, S., Saito, N., Kirigaya, H., et al. Impairment of coronary flow reserve evaluated by phase contrast cine-magnetic resonance imaging in patients with heart failure with preserved ejection fraction. J Am Heart Assoc, 5, 2016, e002649.
89. Srivaratharajah, K., Coutinho, T., deKemp, R., et al. Reduced myocardial flow in heart failure patients with preserved ejection fraction. Circ Heart Fail, 9, 2016, e002562.
90. Mohammed, S.F., Hussain, S., Mirzoyev, S.A., Edwards, W.D., Maleszewski, J.J., Redfield, M.M., Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131 (2015), 550–559.
91. Paulus, W.J., Tschöpe, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
92. Arbustini, E., Dal Bello, B., Morbini, P., et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 82 (1999), 269–272.
93. Bairey Merz, C.N., Shaw, L.J., Reis, S.E., et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 47 (2006), S21–S29.
94. Hochman, J.S., Tamis, J.E., Thompson, T.D., et al., for the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med 341 (1999), 226–232.
95. Taqueti, V.R., Shaw, L.J., Cook, N.R., et al. Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with severely impaired coronary flow reserve, not obstructive disease. Circulation 135 (2017), 566–577.
96. Taqueti, V.R., Sex differences in the coronary system. Adv Exp Med Biol 1065 (2018), 257–278.
97. Taqueti, V.R., Dorbala, S., Wolinsky, D., et al. Myocardial perfusion imaging in women for the evaluation of stable ischemic heart disease-state-of-the-evidence and clinical recommendations. J Nucl Cardiol 24 (2017), 1402–1426.
98. van de Hoef, T.P., van Lavieren, M.A., Damman, P., et al. Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity. Circ Cardiovasc Interv 7 (2014), 301–311.
99. Abdallah, M.S., Wang, K., Magnuson, E.A., et al., for the FREEDOM Trial Investigators. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA 310 (2013), 1581–1590.
100. Dagenais, G.R., Lu, J., Faxon, D.P., et al., for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation 123 (2011), 1492–1500.
101. Pijls, N.H., Fearon, W.F., Tonino, P.A., et al., for the FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol 56 (2010), 177–184.
102. Weintraub, W.S., Spertus, J.A., Kolm, P., et al., for the COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 359 (2008), 677–687.
103. van Kranenburg, M., Magro, M., Thiele, H., et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. J Am Coll Cardiol Img 7 (2014), 930–939.
104. Bulluck, H., Foin, N., Tan, J.W., Low, A.F., Sezer, M., Hausenloy, D.J., Invasive assessment of the coronary microcirculation in reperfused ST-segment-elevation myocardial infarction patients: where do we stand?. Circ Cardiovasc Interv, 10, 2017, e004373.
105. Bravo, P.E., Bergmark, B.A., Vita, T., et al. Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy. Eur Heart J 39 (2018), 316–323.
106. Mc Ardle, B.A., Davies, R.A., Chen, L., et al. Prognostic value of rubidium-82 positron emission tomography in patients after heart transplant. Circ Cardiovasc Imaging 7 (2014), 930–937.
107. Marinescu, M.A., Löffler, A.I., Ouellette, M., Smith, L., Kramer, C.M., Bourque, J.M., Coronary microvascular dysfunction, microvascular angina, and treatment strategies. J Am Coll Cardiol Img 8 (2015), 210–220.
108. Shaw, L.J., Berman, D.S., Maron, D.J., et al., for the COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117 (2008), 1283–1291.
109. Gould, K.L., Ornish, D., Scherwitz, L., et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 274 (1995), 894–901.
110. Quercioli, A., Montecucco, F., Pataky, Z., et al. Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. Eur Heart J 34 (2013), 2063–2073.
111. Guethlin, M., Kasel, A.M., Coppenrath, K., Ziegler, S., Delius, W., Schwaiger, M., Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 99 (1999), 475–481.
112. Villano, A., Di Franco, A., Nerla, R., et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol 112 (2013), 8–13.
113. McMurray, J.J., Packer, M., Desai, A.S., et al., for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
114. Ridker, P.M., Everett, B.M., Thuren, T., et al., for the CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
115. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
116. Zinman, B., Wanner, C., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
117. Schmaier, A.A., Taqueti, V.R., A lack of reserve: recognizing the large impact of small vessels in the heart. Circulation 138 (2018), 424–428.